Post

New research · Endocrinology
European journal of haematology · 23h
Cohort studyEuropean journal of haematology · 2026

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

S Russo, I Capodanno, M Tiribelli … R Latagliata
Read paper
EndocrinologyCohort study

Diabetic patients with chronic myeloid leukemia have lower major molecular response at 12 months.

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

S Russo et al. · European journal of haematology · 2026
Background

Limited data are available regarding patients with newly diagnosed chronic myeloid leukemia (CML) and concomitant diabetes mellitus (DM).

Methods

Hence, we retrospectively analyzed 2149 patients with newly diagnosed chronic phase (CP) CML to compare clinical characteristics, choice of frontline therapy, early adverse events, and molecular responses between patients with or without DM.

55.9%
Results
vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
More results

Among this cohort of 2149 patients, 241 patients (11.2%) had DM at CML diagnosis.

Discontinuation by the 12th month occurred in 24.2% of diabetic patients versus 19.4% of nondiabetics (p = 0.031), mainly for hematologic toxicity.

More results

Among diabetic patients, a trend toward better molecular responses was observed in patients receiving metformin (p = 0.068).

“
Conclusion

In conclusion, DM represents a clinically meaningful comorbidity in newly diagnosed CML-CP, and seems to define a subgroup with distinct features, influencing both treatment decisions and early outcomes.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Cohort Study
OR 18.90
far higher odds of fatty-liver inflammation with scarring at the top blood-marker level
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
AI / Informatics
C-index = 96.0%
The model accurately predicted when initial leukemia treatment would not work
Cohort Study
97.30%
The AI model correctly identified aplastic anemia or myelodysplastic syndromes 97.30% of the time.
Review
30-37%
SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths